Tech Session VII: Delivery to the Nervous System II
Targeted glucose dendrimer ketamine therapy protects against refractory status epilepticus in mice.
Friday, July 18, 2025
8:54 AM – 9:05 AM EDT
Introduction: Refractory status epilepticus (RSE) is a life-threatening neurological emergency characterized by ongoing seizures that rapidly modify neuronal activity and synaptic function, resulting in neurodegeneration, neuroinflammation, and abnormal neurogenesis. Ketamine is a non-competitive NMDA antagonist investigated for RSE, but requires invasive administration and is associated with significant side effects. In this study, we leveraged increased neuronal glucose uptake during seizures to facilitate ketamine transport specifically to hyperactive neurons via glucose-dendrimer ketamine nano-therapy.
Learning Objectives:
At the completion of this activity, participants will know
learn about novel glucose dendrimer ketamine therapy for multiple CNS disorders.
gain insights into the translational relevance of improved anti-seizure ketamine therapy.
learn how this improved GD-Ketamine therapy does not have off-target effects like free ketamine.
